The purposes of the study is to determine whether blood sugar control is different between Lantus and a third oral anti-diabetic agent when added to patients who fail a thiazolidinedione and sulfonylurea or metformin combination.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
240
Aventis
Bridgewater, New Jersey, United States
To determine the difference in glycemic control as measured by HbA1C between substituting the TZD with insulin glargine and adding a third oral agent in patients who fail a TZD/sulfonylurea or TZD/metformin combination therapy
Time frame: During the Study Conduct
Occurrence of hypoglycemia
Time frame: During the study conduct
Change in fasting plasma glucose
Time frame: During the study conduct
Percentage of patients achieving HbA1C less than or equal to 7%
Time frame: During the study conduct
Time to glycemic control
Time frame: During the study conduct
Change in body weight
Time frame: During the study conduct
Change in serum lipid profile
Time frame: During the study conduct
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.